Katafigiotis Ioannis, Sfoungaristos Stavros, Duvdevani Mordechai, Mitsos Panagiotis, Roumelioti Eleni, Stravodimos Konstantinos, Anastasiou Ioannis, Constantinides Constantinos A
1st University Urology Clinic Laiko Hospital, Athens.
Arch Ital Urol Androl. 2016 Mar 31;88(1):47-51. doi: 10.4081/aiua.2016.1.47.
Primary adenocarcinoma of the seminal vesicles (SV) are extremely rare and approximately only 60 cases have been reported in the literature. Due to the lack of specific symptoms the patients often present in an advanced stage of their disease. The only clinical examination that can indicate the presence of a neoplasm in the SVs is the digital rectal examination (DRE). Serum prostatic specific antigen (PSA) and prostate specific acid phosphatase (PAP) are usually normal in patients with primary adenocarcinoma of the SV and only CA-125 can be proved a useful blood biomarker contributing to the diagnosis and the follow up of the SV adenocarcinoma. Computed tomography (CT) and magnetic resonance imaging (MRI) and FDG-PET/CT have been used for the diagnosis and the staging of the SV adenocarcinoma. Various combinations of radical surgery, radiotherapy androgen deprivation therapy and chemotherapy have been proposed for the management of the disease but the prognosis is poor and the mean survival is two years after the diagnosis.
精囊原发性腺癌极为罕见,文献报道约仅60例。由于缺乏特异性症状,患者常以疾病晚期就诊。唯一能提示精囊存在肿瘤的临床检查是直肠指检(DRE)。精囊原发性腺癌患者的血清前列腺特异性抗原(PSA)和前列腺特异性酸性磷酸酶(PAP)通常正常,只有CA - 125可被证明是有助于精囊腺癌诊断及随访的有用血液生物标志物。计算机断层扫描(CT)、磁共振成像(MRI)及氟脱氧葡萄糖正电子发射断层显像/计算机断层扫描(FDG - PET/CT)已用于精囊腺癌的诊断及分期。对于该病的治疗已提出了根治性手术、放疗、雄激素剥夺治疗及化疗的各种联合方案,但预后较差,诊断后平均生存期为两年。